Breast Cancer Therapeutics Pipeline Analysis Market Expected to Reach USD 7.8 Billion at a CAGR of 58.3% From 2015 to 2023: Transparency Market Research

Aug 11, 2015, 08:30 ET from Transparency Market Research

ALBANY, New York, August 11, 2015 /PRNewswire/ --

According to a new market research report published by Transparency Market Research "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023", the global breast cancer therapeutics market was valued at USD 55.5 million in 2015 and is estimated to reach USD 7,853.1 million in 2023 at a CAGR of 58.3% from 2015 to 2023.

Browse Market Research Report on Breast Cancer Therapeutics: Pipeline Analysis Market:

Cancer is a disease in which abnormal cells grow out of control and invade other normal cells of the body. According to the World Health Organization (WHO), there are more than 200 types of cancer, accounting for over 14.1 million new cases globally every year. Breast cancer is the second most prevalent type of cancer worldwide. According to the World Cancer Research Fund International, breast cancer is the most common cancer in women worldwide, with nearly 1.7 million cases diagnosed in 2012. Rising prevalence of breast cancer is one of the major factor driving the growth of effective and novel therapies. Globally, breast cancer is the most common invasive cancer in women. Nearly 1.7 million new cases of breast cancer were diagnosed in 2013. Breast cancer is the second most common cause of death in women in the U.S., after lung cancer. According to the American Cancer Society, an estimated 231,840 women would be diagnosed with breast cancer in 2015 in the U.S. alone. A report published by the International Agency for Research on Cancer stated that 458,337 incidences of breast cancer in women were recorded in Europe in 2012. Belgium had the highest rate of breast cancer, followed by Denmark and France.

Get Sample Report Copy of Breast Cancer Therapeutics: Pipeline Analysis Market:

Incidence rates of breast cancer are much higher in developed countries compared to developing countries. Oral contraceptives and hormone replacement therapy, excessive alcohol consumption, not having children or having children at an older age, obesity, smoking, and sedentary lifestyle are the major risk factors that could cause breast cancer. Hence, incidence rates of breast cancer are highest in developed countries where the prevalence of these risk factors is much greater. According to the Breast Cancer Organization, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. in 2015, along with 60,290 new cases of non-invasive (in situ) breast cancer and about 2,350 new cases of invasive breast cancer in men. The survival rate of the patients with cancer depends upon the stage in which the cancer is diagnosed.

Browse Press Release of Breast Cancer Therapeutics: Pipeline Analysis Market:

The pipeline of breast cancer is strong and rich in number of research molecules especially in phase I and phase II clinical studies. Drugs currently in phase III clinical trials are NKTR-102 (Nektar Therapeutics), DOXIL (Johnson & Johnson Pharmaceutical Research & Development, L.L.C), and trastuzumab emtansine + pertuzumab (Hoffmann-La Roche AG), BKM120 (Novartis).

Among all the pipeline drugs in phase III, Neratinib (Puma Biotechnology, Inc.) is estimated to generate maximum revenue by 2023. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, or EGFRs, HER1, HER2, and HER4. Palbociclib + Fulvestrant (Pfizer, Inc.) is estimated to be the second most promising drug and is expected to provide promising therapeutic results in the treatment of breast cancer. Palbociclib is an investigational drug and an oral targeted agent that selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 in order to regain cell cycle control and inhibit proliferation of tumor cells. The pipeline of breast cancer therapeutics is expected to generate significant revenue after commercialization primarily due to rising prevalence of breast cancer and associated mortality globally. Existing manufacturers and new entrants are therefore recommended to focus on the key growth areas and capitalize on the potential growth opportunities.

Other Reports Published by Transparency Market Research:  

Key players in the breast cancer pipeline market are Pfizer, Inc., Puma Biotechnology, Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and F. Hoffmann-La Roche AG. However, the therapeutic pattern is shifting from traditional chemotherapy to biological treatment.

Browse Upcoming Market Research Reports:  

The global breast cancer therapeutics market has been segmented into:

Global Breast Cancer Therapeutics Market: Pipeline Analysis, by Drugs (Phase III) 

  • Palbociclib (PD-0332991) + Exemestane
  • NK105
  • BKM120
  • NKTR-102
  • Neratinib
  • Olaparib
  • DOXILs
  • ABP 980
  • CT-P6
  • Trastuzumab emtansine
  • Phase II Drug Candidates
  • Phase I Drug Candidates

Browse All Other Pharmaceutical Market Research Reports:

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

SOURCE Transparency Market Research